Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples
- 1 May 2003
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 17 (8) , 1258-1261
- https://doi.org/10.1097/00002030-200305230-00021
Abstract
A panel of 245 clinical samples with known treatment histories was retrospectively evaluated for cross-resistance to new protease inhibitors (PI). Samples with resistance to previously approved PI displayed high cross-resistance to atazanavir, whereas cross-resistance to amprenavir was considerably lower. A similar cross-resistance profile was observed for lopinavir, if a higher cut-off for resistance (9.5-fold) was applied. The enhanced efficacy of boosted PI is discussed with respect to clinically relevant cut-offs for drug resistance.Keywords
This publication has 9 references indexed in Scilit:
- Antiretroviral Treatment for Adult HIV Infection in 2002JAMA, 2002
- Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment FailureA Randomized TrialJAMA, 2002
- Combination of Protease Inhibitors for the Treatment of HIV-1-Infected Patients: A Review of Pharmacokinetics and Clinical ExperienceAntiviral Therapy, 2002
- Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse‐Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1–Infected Protease Inhibitor–Experienced PatientsThe Journal of Infectious Diseases, 2002
- Amprenavir Inhibitory Quotient and Virological Response in Human Immunodeficiency Virus-Infected Patients on an Amprenavir-Containing Salvage Regimen without or with RitonavirAntimicrobial Agents and Chemotherapy, 2002
- Low Level of Cross-Resistance to Amprenavir (141W94) in Samples from Patients Pretreated with Other Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2000
- In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632Antimicrobial Agents and Chemotherapy, 2000
- Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapiesAIDS, 1999
- Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitorsJournal of Clinical Virology, 1999